Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Gender Preference	None
Age Group	18 - 80 years
Research Start Date	April 20, 2012
Research End Date	June 14, 2013
Principal Investigator	Sif Hansdottir, MD
Description	This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH). Please refer to www.clinicaltrials.gov identifier NCT01457781 for further information.
Contact Info	Pulmonary Hypertension Program Page Scovel, RN phone: 319-356-1028 fax: 319-356-7087 email: page-scovel@uiowa.edu
Keywords	span itemProp='description'>Heart ; High blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension ;

Contact